The P-II study assesses APHD-012 (12g, oral glucose formulation, QD) or APHD-012P vs matching PBO in prediabetic & diabetic adults or healthy individuals (n=~30) for 6wks., followed by 4wks. washout & switching treatments for the next 6wks.
The OGTT blood glucose levels at 120min. post-challenge reduced from 9.0±6 to 7.9±0.6 mmol/L vs 8.8±0.4 to 8.5±0.6 mmol/L after 6wks. in all of them while 13.2±7 to 11.6±0.5 mmol/L vs 11.4±0.5 to 12.0±0.6 mmol/L was observed in all diabetic patients
In prediabetic patients, OGTT blood glucose levels reduced from 8.7±4 to 6.8±0.5 mmol/L vs 8.6±0.4 to 8.2±0.6 mmol/L and OGTT AUC 0-120 minutes decreased from 1261±47 to 1163±36 min*mmol/L vs 1250±45 to 1225±53 min*mmol/L. Data from P-II obesity study is expected in H2’24
Ref: Aphaia Pharma | Image: Aphaia Pharma
Related News:- Innovent Reports the NMPA’s NDA Acceptance of IBI311 for Treating Thyroid Eye Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
